Pfizer Inc. and China’s Innovent Biologics have announced a global licensing and collaboration agreement. The deal, valued at up to $10.5 billion, is set to develop 12 early-stage cancer drugs. The ...

A study of nearly 500 domestic cats uncovered similarities between cancer gene mutations in felines and humans.

A cancer-killing virus has stopped pancreatic tumours from growing and spreading in three people in an initial safety trial, ...

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.

Learn more Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer ...

Mercury in Cancer creates a stronger focus on emotional understanding, personal communication, thoughtful reflection, and ...

E-cigarettes may carry cancer risks of their own, researchers warn. A doctor explains what people who vape and parents should ...

One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Pfizer and Innovent Biologics signed a licensing agreement to research and develop 12 cancer medicines. The agreement includes licensing, co-development and co-commercialization across the ...

Our scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit cancer growth.

The FDA proposes reducing animal testing for some cancer drugs as part of an effort to speed up R&D timelines with rodent-only trials in some cases. Read more here.